Patents by Inventor Elfrida Benjamin

Elfrida Benjamin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20260097027
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: April 21, 2025
    Publication date: April 9, 2026
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry disease in patients having a mutation in the GLA gene
    Patent number: 12594268
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: April 7, 2026
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Elfrida Benjamin
  • Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene
    Patent number: 12414944
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Grant
    Filed: January 31, 2022
    Date of Patent: September 16, 2025
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Elfrida Benjamin
  • Methods of treating fabry patients having renal impairment
    Patent number: 12280042
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: April 22, 2025
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
    Publication number: 20250082621
    Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.
    Type: Application
    Filed: October 26, 2020
    Publication date: March 13, 2025
    Applicant: AMICUS THERAPEUTICS, INC.
    Inventors: Elfrida Benjamin, Hung V. Do, Xiaoyang Wu, John Flanagan, Brandon Alan Wustman
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12109205
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 8, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
    Publication number: 20240293436
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Application
    Filed: September 25, 2023
    Publication date: September 5, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Elfrida Benjamin, Xiaoyang Wu
  • METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE
    Publication number: 20240277687
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Application
    Filed: October 2, 2023
    Publication date: August 22, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventor: Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042489
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042488
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042490
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
    Publication number: 20240207295
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Application
    Filed: September 25, 2023
    Publication date: June 27, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Elfrida Benjamin, Xiaoyang Wu
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20240122911
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: April 18, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11903938
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 20, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry disease in patients having a mutation in the GLA gene
    Patent number: 11833164
    Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: December 5, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Elfrida Benjamin, Xiaoyang Wu
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20230381165
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: November 30, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20230381164
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: November 30, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11826360
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: November 28, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11813255
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: November 14, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11786516
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: October 17, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin